Lanean...
Pharmacodynamics of natalizumab extended interval dosing in MS
OBJECTIVE: To determine if the concentration and saturation of natalizumab (NTZ) administration at extended interval dosing (EID; every 5–8 weeks) over 18 months is able to be maintained in the range considered adequate to sustain the clinical efficacy of NTZ. METHODS: In a cross-sectional assessmen...
Gorde:
| Argitaratua izan da: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Lippincott Williams & Wilkins
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057061/ https://ncbi.nlm.nih.gov/pubmed/32019876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000672 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|